Jasmanda H. Wu
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Jasmanda H. Wu has a total of 7 co-authors. Here are the top co-authors by number of shared publications:
- David R. Lairson
Department of Management, Policy, and Community Health, University of Texas Health Science Center at Houston School of Public Health, Houston, Texas
1 shared publication - Frank D. Gianfrancesco
HECON Associates, Inc. Montgomery Village, MD, USA
1 shared publication - Gahan J. Pandina
Johnson and Johnson Pharmaceutical Research and Development, Titusville, NJ, USA
1 shared publication Man C. Fung
1 shared publication- Ramy A. Mahmoud
Ethicon, Inc. (a Johnson & Johnson Company), PO Box 151, Route 22 West, Somerville, NJ 08876-0151, USA
1 shared publication - Ruey H Wang
HECON Associates Inc., 9833 Whetstone Drive, Montgomery Village, MD 20886, USA
1 shared publication
Latest Publications
- Open Access
- 1 January 2009
- Published by Springer Nature in Annals of General Psychiatry
- Vol. 8 (1) , 5
Potential bias in testing for hyperprolactinemia and pituitary tumors in risperidone-treated patients: a claims-based study
A reporting association of risperidone with pituitary tumors has been observed. Because such tumors are highly prevalent, there may be other reasons why they were revealed in association with risperidone treatment. We assessed two potential explanations: disproportionately more prolactin assessment and head/brain imaging in risperidone-treated patients vs patients treated with other antipsychotics.
- 1 January 2009
- Published by Springer Nature in Annals of General Psychiatry
- Vol. 8 (1) , 5
Open AccessPotential bias in testing for hyperprolactinemia and pituitary tumors in risperidone-treated patients: a claims-based study
A reporting association of risperidone with pituitary tumors has been observed. Because such tumors are highly prevalent, there may be other reasons why they were revealed in association with risperidone treatment. We assessed two potential explanations: disproportionately more prolactin assessment and head/brain imaging in risperidone-treated patients vs patients treated with other antipsychotics.
- 1 March 2004
- Published by Elsevier in Value in Health
- Vol. 7 (2) , 175-185
Cost-Effectiveness Analysis of Interventions to Enhance Mammography Compliance Using Computer Modeling (CAN*TROL)
- 1 March 2004
- Published by Elsevier in Value in Health
- Vol. 7 (2) , 175-185
Cost-Effectiveness Analysis of Interventions to Enhance Mammography Compliance Using Computer Modeling (CAN*TROL)